Trust AI in Health - Are We Ready?

Artificial Intelligence (AI) has sparked tremendous interest in healthcare, playing key roles in assistive decision making, improving clinical workflow, cost-effectiveness, and most importantly patient outcomes and experience. Much of the focus in the past has been on technology development. In the evolving relationship between humans and AI, trust is the one mechanism that will expedite AI adoption by healthcare professionals.

Can we understand how AI makes medical decisions, is it a black box? Will clinicians trust an AI-based system? What are the factors that influence human trust in AI? Can trust in AI be optimised to improve decision-making processes? For this journal club, we have invited experts from the Ministry of Health, National Supercomputing Centre, NUS Biomedical Engineering and SingHealth to discuss AI governance and regulation, pearls and pitfalls to accelerate AI adoption within the healthcare setting. 

Date: 20 January 2022, Thursday
Time: 7:00pm - 8:00pm (Singapore Time / UTC +8)

Programme:
7:00pm - 7:05pm: Introduction and Welcome
7:05pm - 8:00pm: Fireside chat on Trust AI in Health - Are We Ready? with:

• Sutowo Wong, Director, AI and Analytics, Ministry of Health
• Bernard Tan, Director, Strategy, Planning and Engagement, National Supercomputing Centre Singapore
• Prof Carolyn Lam, Professor, Duke-NUS Medical School and Senior Consultant, National Heart Centre Singapore
• Prof Dean Ho, Provost's Chair Professor, Director – The N.1 Institute for Health (N.1) & The Institute for Digital Medicine (WisDM) and Head – Biomedical Engineering, National University of Singapore
• Moderator: A/Prof Daniel Ting, Director - Artificial Intelligence (AI) Programme, SingHealth and Head of AI & Digital Innovation, Singapore Eye Research Institute (SERI)

Speakers' Profiles:
Sutowo Wong, Director, AI and Analytics, Ministry of Health

Sutowo is the Director, Data Analytics Division at Ministry of Health (MOH) Singapore. He leads a team of data scientists, statisticians and health economists in applying artificial intelligence (AI), machine learning (ML), operations research, systems modelling, geospatial analytics, forecasting, econometrics, visualisation and primary research in support of MOH’s priorities in policy formulation and review, service planning and operations.

He is responsible for leading health AI strategy and building ecosystem enablers needed, i.e. AI governance, data and IT platforms, funding, to support the development and deployment of impactful, scalable, responsible AI solutions in the healthcare sector data. He is also responsible for capability development, publication, partnership, and outreach regarding data analytics and AI in MOH. Before his role in MOH, he was in various analytics leadership roles with experience across various domains such as customer, fraud/risk, HR and operations.

He worked with organisations in public service, healthcare, pharmaceuticals, CPG, retail, telco, banking, insurance, energy, airlines and hospitality in Southeast Asia, China, India and Japan.

Bernard Tan, Director, Strategy, Planning and Engagement, National Supercomputing Centre Singapore

Bernard Tan is the Director for Strategy, Planning and Engagements for National Supercomputing Centre Singapore (NSCC), under A*Star. He has been instrumental in the strategic planning and deployment of national advanced research programs that utilise Supercomputing and Quantum Computing capabilities.

With over 20 years of global technology experience with multinational companies like IBM, Red Hat, and as a technopreneur, Bernard is always at the forefront of bringing emerging technologies to the commercial and public sectors with his global markets knowledge hands-on approach.

Prof Carolyn Lam, Professor, Duke-NUS Medical School and Senior Consultant, National Heart Centre Singapore

Dr Lam is a Professor at the Duke-National University of Singapore and Senior Consultant at the National Heart Centre Singapore specialising in heart failure and recognised globally for expertise in heart failure with preserved ejection fraction. She is a world-renown clinical trialist, with her work as part of the global steering committee of the PARAGON and EMPEROR-Preserved trials contributing to the first FDA-approved treatment for HFpEF to date as well as the first robustly positive outcomes trial in HFpEF to date. Her leadership is recognised in her appointment to the 2021 European Society of Cardiology Heart Failure Guidelines Task Force. She is a recipient of the NMRC Senior Investigator Clinician Scientist Award, Programme Lead of A*STaR’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), Principal Investigator of ASIAN-HF (multinational study across 11 Asian countries), and Executive Committee member/ lead of multiple global clinical trials.

She has published >350 articles in journals including NEJM, JAMA, Lancet, Circulation, and European Heart Journal; and has been recognized in the Clarivate Highly cited Researcher 2021 in the field of Clinical Medicine and as a World Expert by Expertscape’s PubMed-based algorithms (top 0.1% of scholars writing about Heart Failure over the past ten years. She serves as Associate Editor for Circulation and the European Journal of Heart Failure. Dr Lam is heard weekly on the global podcast “Circulation On The Run” and seen regularly on television as the Resident Doctor of “Body and Soul” by MediaCorp Singapore.

Prof Dean Ho, Provost's Chair Professor, Director – The N.1 Institute for Health (N.1) & The Institute for Digital Medicine (WisDM) and Head – Biomedical Engineering, National University of Singapore

Professor Dean Ho is currently Provost’s Chair Professor, Director of The N.1 Institute for Health (N.1), Director of The Institute for Digital Medicine (WisDM) and Head of the Department of Biomedical Engineering at the National University of Singapore.

Prof. Ho and collaborators successfully developed and validated CURATE.AI, a powerful digital medicine platform that has optimized human treatment for broad indications ranging from oncology to infectious diseases. He co-led the first inhuman clinical trials that have resulted in completely halted disease progression and durable patient responses that substantially outperformed standard of care approaches.

Moderator's Profile:
A/Prof Daniel Ting, Director - Artificial Intelligence (AI) Programme, SingHealth and Head of AI & Digital Innovation, Singapore Eye Research Institute (SERI)

Associate Professor Daniel Ting is the Director of SingHealth AI Programme, Head of AI and Digital Innovation in Singapore Eye Research Institute (SERI), Associate Professor in Ophthalmology with Duke-NUS Medical School Singapore, and Consultant Vitreo-Retinal Surgeon in Singapore National Eye Centre.

The SingHealth Cluster AI Program was established in April 2021 with the vision to harness the power of AI for Academic Medicine of Tomorrow. The key focus areas for this programme are to develop more AI-powered clinical solutions using different cutting edge technologies and rapidly bring these technologies to the bedside for clinical implementation and scale them in the global setting. Furthermore, this programme hopes to build a critical mass of the current and next generation of AI literate practitioners within the healthcare space.

In the global setting, Dr Ting serves in several AI executive committees (STARD-AI, DECIDE-AI, American Academy of Ophthalmology) and AI editorial boards (NPJ Digital Medicine, Frontiers in Medicine and Digital Health). To date, he has published >200 peer-reviewed papers in highly prestigious journals such as JAMA, NEJM, Lancet, Nature Medicine, etc., and recently been ranked the world’s most influential deep learning researcher across clinical and technical domains in healthcare for the past ten years (2010-2021) by the ExpertScape. He was also the visiting Fulbright Scholar to Johns Hopkins University in 2017.